Sowell Financial Services LLC Takes $201,000 Position in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Sowell Financial Services LLC acquired a new position in Alnylam Pharmaceuticals, purchasing 616 shares valued at approximately $201,000 in the second quarter.
• Several other institutional investors, including Wealth Enhancement Advisory Services LLC and GAMMA Investing LLC, have also significantly increased their stakes in Alnylam, indicating strong institutional interest.
• Alnylam's shares have recently been rated as "buy" or "outperform" by multiple analysts, with target price estimates reaching as high as $520.00 from Bank of America.

Sowell Financial Services LLC purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 616 shares of the biopharmaceutical company's stock, valued at approximately $201,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth $243,000. Park Square Financial Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth $28,000. Wealth Enhancement Advisory Services LLC boosted its position in Alnylam Pharmaceuticals by 94.7% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 12,566 shares of the biopharmaceutical company's stock valued at $2,957,000 after purchasing an additional 6,112 shares in the last quarter. Versant Capital Management Inc grew its stake in Alnylam Pharmaceuticals by 76.8% in the first quarter. Versant Capital Management Inc now owns 336 shares of the biopharmaceutical company's stock valued at $91,000 after purchasing an additional 146 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in Alnylam Pharmaceuticals by 30,759.4% in the first quarter. GAMMA Investing LLC now owns 166,332 shares of the biopharmaceutical company's stock valued at $44,913,000 after purchasing an additional 165,793 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Michael W. Bonney sold 11,250 shares of the company's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the completion of the transaction, the director owned 16,804 shares in the company, valued at $7,561,800. This represents a 40.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,396 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $453.27, for a total value of $632,764.92. Following the completion of the transaction, the executive vice president owned 22,719 shares in the company, valued at approximately $10,297,841.13. This trade represents a 5.79% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 75,594 shares of company stock valued at $33,968,256. 1.50% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms have recently weighed in on ALNY. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Friday, September 5th. JPMorgan Chase & Co. upped their price target on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Royal Bank Of Canada raised their price objective on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an "outperform" rating in a research report on Friday, September 19th. Bank of America boosted their target price on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a "buy" rating in a research note on Wednesday, September 17th. Finally, Oppenheimer upgraded Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 price target for the company in a research note on Monday, August 4th. Twenty-four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $439.58.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $446.40 on Friday. The company has a 50 day moving average price of $428.51 and a 200-day moving average price of $331.46. The firm has a market cap of $58.51 billion, a price-to-earnings ratio of -180.73 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $484.21. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm had revenue of $773.69 million for the quarter, compared to analysts' expectations of $633.54 million. During the same period last year, the firm earned ($0.13) EPS. The company's quarterly revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.